Application of Lenalidomide on Diffused Large B-cell Lymphoma: Salvage, Maintenance, and Induction Treatment

Overview

Journal Chin Med J (Engl)

Specialty General Medicine

Date 2018 Oct 19

PMID 30334543

Citations 2

Authors

Li-Yangxue Ma

Li Su

Affiliations

Soon will be listed here.

Citing Articles

Efficacy and Safety of Lenalidomide Monotherapy for Relapsed/Refractory Diffuse Large B Cell Lymphoma: Systematic Review and Meta-Analysis.

Li J, Zhou J, Guo W, Wang X, Zhao Y, Bai O Front Oncol. 2021; 11:756728.

PMID: 34926259 PMC: 8674688. DOI: 10.3389/fonc.2021.756728.

Characterization of Artificial Pneumothorax-Unrelated Pyothorax-Associated Lymphoma.

Chen G, Xia Z, Jin J, Yu B, Cao J J Oncol. 2021; 2021:3869438.

PMID: 33564306 PMC: 7850845. DOI: 10.1155/2021/3869438.

References

Gisselbrecht C, Glass B, Mounier N, Singh Gill D, Linch D, Trneny M . Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010; 28(27):4184-90. PMC: 3664033. DOI: 10.1200/JCO.2010.28.1618. View

Ivanov V, Coso D, Chetaille B, Esterni B, Olive D, Aurran-Schleinitz T . Efficacy and safety of lenalinomide combined with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma. Leuk Lymphoma. 2014; 55(11):2508-13. DOI: 10.3109/10428194.2014.889822. View

Nowakowski G, Chiappella A, Witzig T, Spina M, Gascoyne R, Zhang L . ROBUST: Lenalidomide-R-CHOP versus placebo-R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma. Future Oncol. 2016; 12(13):1553-63. PMC: 5551933. DOI: 10.2217/fon-2016-0130. View

Ito T, Ando H, Suzuki T, Ogura T, Hotta K, Imamura Y . Identification of a primary target of thalidomide teratogenicity. Science. 2010; 327(5971):1345-50. DOI: 10.1126/science.1177319. View

Reddy N, Thieblemont C . Maintenance therapy following induction chemoimmunotherapy in patients with diffuse large B-cell lymphoma: current perspective. Ann Oncol. 2017; 28(11):2680-2690. DOI: 10.1093/annonc/mdx358. View

Hernandez-Ilizaliturri F, Deeb G, Zinzani P, Pileri S, Malik F, Macon W . Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype. Cancer. 2011; 117(22):5058-66. DOI: 10.1002/cncr.26135. View

Solomon L, Batista C, DeKoter R . Lenalidomide modulates gene expression in human ABC-DLBCL cells by regulating IKAROS interaction with an intronic control region of SPIB. Exp Hematol. 2017; 56:46-57.e1. DOI: 10.1016/j.exphem.2017.09.002. View

Pellagatti A, Jadersten M, Forsblom A, Cattan H, Christensson B, Emanuelsson E . Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients. Proc Natl Acad Sci U S A. 2007; 104(27):11406-11. PMC: 1892786. DOI: 10.1073/pnas.0610477104. View

Dredge K, Horsfall R, Robinson S, Zhang L, Lu L, Tang Y . Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. Microvasc Res. 2005; 69(1-2):56-63. DOI: 10.1016/j.mvr.2005.01.002. View

10.

Czuczman M, Trneny M, Davies A, Rule S, Linton K, Wagner-Johnston N . A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Clin Cancer Res. 2017; 23(15):4127-4137. PMC: 8171498. DOI: 10.1158/1078-0432.CCR-16-2818. View

11.

Witzig T, Vose J, Zinzani P, Reeder C, Buckstein R, Polikoff J . An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. Ann Oncol. 2011; 22(7):1622-1627. DOI: 10.1093/annonc/mdq626. View

12.

Wang M, Fowler N, Wagner-Bartak N, Feng L, Romaguera J, Neelapu S . Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial. Leukemia. 2013; 27(9):1902-9. DOI: 10.1038/leu.2013.95. View

13.

Reddy N, Hernandez-Ilizaliturri F, Deeb G, Roth M, Vaughn M, Knight J . Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo. Br J Haematol. 2007; 140(1):36-45. DOI: 10.1111/j.1365-2141.2007.06841.x. View

14.

Zinzani P, Rigacci L, Cox M, Devizzi L, Fabbri A, Zaccaria A . Lenalidomide monotherapy in heavily pretreated patients with non-Hodgkin lymphoma: an Italian observational multicenter retrospective study in daily clinical practice. Leuk Lymphoma. 2014; 56(6):1671-6. DOI: 10.3109/10428194.2014.964702. View

15.

Thieblemont C, Tilly H, Gomes Da Silva M, Casasnovas R, Fruchart C, Morschhauser F . Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone. J Clin Oncol. 2017; 35(22):2473-2481. DOI: 10.1200/JCO.2017.72.6984. View

16.

Krieg S, Ullrich E . Novel immune modulators used in hematology: impact on NK cells. Front Immunol. 2013; 3:388. PMC: 3539673. DOI: 10.3389/fimmu.2012.00388. View

17.

Zinzani P, Pellegrini C, Argnani L, Broccoli A . Prolonged disease-free survival in elderly relapsed diffuse large B-cell lymphoma patients treated with lenalidomide plus rituximab. Haematologica. 2016; 101(9):e385-6. PMC: 5060037. DOI: 10.3324/haematol.2016.147256. View

18.

Garciaz S, Coso D, Schiano De Colella J, Bouabdallah R . Lenalidomide for the treatment of B-cell lymphoma. Expert Opin Investig Drugs. 2016; 25(9):1103-16. DOI: 10.1080/13543784.2016.1208170. View

19.

Zinzani P, Pellegrini C, Gandolfi L, Stefoni V, Quirini F, Derenzini E . Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial. Clin Lymphoma Myeloma Leuk. 2011; 11(6):462-6. DOI: 10.1016/j.clml.2011.02.001. View

20.

Fink E, Ebert B . The novel mechanism of lenalidomide activity. Blood. 2015; 126(21):2366-9. PMC: 4653765. DOI: 10.1182/blood-2015-07-567958. View